Hier finden Sie heraus, welche Diät wirklich zu Ihnen passt.

Die „Advanced Diet Profile Diagnosis“ ordnet jedem genau die Methode zu, mit der er am besten abnehmen kann.

Advanced Diet Profile Diagnosis

Hier erfahren Sie, warum Sie bisher noch nicht mit dem Rauchen aufhören konnten und wie Sie es jetzt endlich schaffen: Mit der ADPD-Diagnose

Liebe zukünftige Biki-Schönheit,

für Sie ist der „Abnehm-Stress“ jetzt endlich beendet!

In den nächsten Minuten klärt sich auf, warum bei Ihnen bisher rein gar nichts funktioniert hat. Warum es für Sie bisher sogar völlig unmöglich war, erfolgreich abzunehmen.

Und es klärt sich, was Ihnen persönlich wirklich hilft. Wie Sie – und zwar Sie ganz individuell – erfolgreich abnehmen können.

Was genau ist ADPD und wie kann man solche Erfolge versprechen? 

ADPD steht für den englischen Ausdruck „Advanced Diet Profile Diagnosis“ und ordnet jeder Frau die Methode zu, mit der sie am besten abnehmen kann.

Diese Diagnose bringt Licht in den Urwald der Methoden und pickt genau die richtige für Sie heraus. Denn wer den falschen Ansatz für sich wählt, kann gar nicht erfolgreich abnehmen.

Weltweit haben bereits über 15 Millionen Menschen mit den hier präsentierten Methoden abgenommen und es werden täglich mehr. Diese Diagnose ist zum ersten Mal in Deutschland online erhältlich! Nehmen Sie sich daher einen Moment Zeit für die Diagnose und finden Sie heraus, welcher Weg für Sie der Richtige ist.

ADPD-Diagnose.org kämpft aus Überzeugung gegen die Lebensmittelindustrie und wurde durch private Mittel finanziert. Darum ist die Diagnose für Sie:

  • Kostenlos
  • Ohne Anmeldung
  • Ohne Angabe von E-Mail-Adresse
  • Ohne Angabe persönlicher Daten

Sie wählen einfach nur die Antwortmöglichkeiten zu den Fragen aus und bekommen anschließend die ADPD-Diagnose direkt hier auf dieser Website.

Was gibt es bei der Diagnose zu beachten?

Weil hierbei die Fragen aus dem Bereich der Persönlichkeitspsychologie und der Tiefenpsychologie eine wichtige Rolle spielen, müssen Sie auf viele Fragen spontan Antworten. Dies ist wichtig, weil die Diagnose unterbewusste Gedanken analysiert.

Damit die Ergebnisse nicht verfälscht werden, haben Sie nur 9 Minuten Zeit, um die Fragen zu beantworten. Dies ist ausreichend Zeit, um die Fragen zu lesen und zu beantworten. Es verhindert aber gleichzeitig, dass Sie zulange über bestimmte Fragen nachdenken. Sobald Sie unten stehend die Diagnose beginnen, erscheint am unteren rechten Rand Ihres Bildschirms die Zeitanzeige.

Wenn Sie zu lange warten, wird die Diagnose automatisch beendet, da das Ergebnis andernfalls verfälscht wird. Führen Sie die Diagnose bitte ein Mal konzentriert durch. Eine Wiederholung ist aufgrund der tiefenpsychologischen Fragen nicht sinnvoll.

Bitte konzentrieren Sie sich daher darauf, die Diagnose in einer Sitzung durchzuführen.

Wissenschaftliche Studien und Literatur zu den Abnehm-Methoden finden Sie unterhalb des Diagnose-Bereichs.

Die ADPD-Diagnose:

Klicken Sie auf das blaue Feld "Weiter->" unten rechts, um mit der ersten Frage zu beginnen. Ihre verbleibende Zeit sehen Sie dann am unteren rechten Bildschirmrand.

Sollten beim Klicken auf das "Weiter ->" Feld, die Antwortmöglichkeiten rot aufleuchten, dann wurde die Antwort nicht richtig angeklickt. Wählen Sie die Antwort einfach erneut aus und fahren Sie fort.


Wissenschaftliche Studien und Literatur

  • Abbot, NC, Stead, LF, White, AR et al. Hypnotherapy for smoking cessation (Cochrane Review). In: The Cochrane Library, Issue 2, Update Software, Oxford. 2001.
  • Aiping, J, Meng, C. Analysis of therapeutic effects of acupuncture on abstinence from smoking. J Tradit Chin Med. 1994; 14:56-63.
  • Arday, DR, Giovino, GA, Schulman, J et al. Cigarette smoking and self-reported health problems among U. S. high school seniors, 1982-1989. Am J Health Promot. 1995; 10: 111-116.
  • Arzneimittelkommission der Deutschen Ärzteschaft. Therapieempfehlungen Tabakabhängigkeit. Arzneiverordnungen in der Praxis, Sonderheft. 2001.
  • AWMF und ÄZQ. Das Leitlinien-Manual. Zeitschrift für ärztliche Fortbildung und Qualitätssicherung. 2000.
  • Balfour, DJK. Neural mechanisms underlying nicotine dependence. Addict. 1994; 89; 1419-1423.
  • Bartecchi, CE et al. The human costs of tobacco use. N Engl J Med. 1994; 330: 907-912.
  • Batra, A, Buchkremer, G. Tabakabhängigkeit – Ein Therapeutenleitfaden. Kohlhammer, Stuttart, 2003.
  • Batra, A, Fagerström, KO. Neue Aspekte der Nikotinabhängigkeit und Raucherentwöhnung. Sucht. 1997. 43, 277 – 282.
  • Batra, A. Bupropion – wirkungsvolle oder nebenwirkungsreiche Raucherentwöhnungstherapie? Sucht. 2001; 47; 294-298.
  • Batra, A. Tabakabhängigkeit – evidenzbasierte Strategien der Behandlung. Zeitschrift für ärztliche Fortbildung und Qualitätssicherung. 2002; 96: 281-286.
  • Batra, A. Tabakabhängigkeit und Raucherentwöhnung bei psychiatrischen Patienten. Fortschr Neurol Psychiatr. 2000b; 68: 80-
  • Batra, A. Tabakabhängigkeit: biologische und psychosoziale Entstehungsbedingungen und Therapiemöglichkeiten. Steinkopff, Darmstadt. 2000a.
  • Behm, FM, Rose, JE. Reducing craving for cigarettes while decreasing smoke intake using capsaicin-enhanced low tar cigarettes.
    Experimental and Clinical Psychopharmacol. 1994; 2: 143-153.
  • Benowitz N. , Gourlay, SG. Carciovascular toxicity of nicotine: implications for nicotine replacement therapy. J Am Coll Cardiol. 1997; 29: 1422-1431.
  • Benowitz, N. Nicotine replacement therapy during pregnancy. JAMA. 1991. 22: 3174-3177.
  • Benowitz, NL et al. Cardiovascular Effects of Nasal and Transdermal Nicotine and Cigarette Smoking. Hypertension. 2002; 39: 1107-1112.
  • Berlin, I, Said, S, Spreux-Varoquaux, O et al. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin Pharmacol Ther. 1995; 58: 444-452.
  • Blondal, T et al. Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up. BMJ. 1999; 318: 285-288.
  • Bobo, JK: Nicotine dependence and alcoholism. Epidemiology and treatment. J Psychoactive Drugs. 1989; 21: 323-329.
  • Bohadana, A et al. Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation. A randomised, double-blind, placebo-controlled trial. Arch Int Med. 2000; 160: 3128-3134.
  • Bolliger, CT. Practical experiences in smoking reduction and cessation. Addiction. 2000; 95 (Suppl 1): 19-24.
  • Bollinger, CT et al. Smoking reduction with oral nicotine inhalers: double blind, randomised clinical traial of efficacy and safety. BMJ. 2000; 321: 329-333.
  • Borrelli, B, Niaura, R, Keuthen, NJ, Goldstein, MG, DePue, JD, Murphy, C, Abrams, DB. Development of major depressive disorder during smoking-cessation treatment. J Clin Psychiatry. 1996; 57: 534-538.
  • Bowen, DJ, Spring, B, Fox, E. Tryptophan and high-carbohydrate diets as adjuncts to smoking cessation therapy. J Behav Med. 1991; 14: 97-110.
  • Brauer, LH, Behm, FM, Westman, EC et al. Naltrexone blockade of nicotine effects in cigarette smokers. Psychopharmacol Berl. 1999; 143: 339-346.
  • Brecklinghaus, I, Lang, P, Greiser, E. Rauchfrei in der Schwangerschaft. Beratungsleitfaden für die gynäkologische Fachpraxis.
    Bundeszentrale für gesundheitliche Aufklärung. Köln. 1999.
  • Breese, CR, Marks, MJ, Logel, J et al. Effect of smoking history on [3H]nicotine binding in human postmortem brain. J Pharmacol Exp Ther. 1997; 282: 7-13.
  • Brengelmann, JC. Informationen und Anleitungen zur Behandlung des Rauchens. Schriftenreihe des Bundesministeriums für Jugend, Familie und Gesundheit. Stuttgart, Kohlhammer, 1976; 27.
  • Breslau, N, Kilbey, MM, Andreski, P. Nicotine dependence and major depression. New evidence from a prospective investigation. Arch Gen Psychiatry. 1993; 50: 31-35.
  • Brown, RA, Lewinsohn, PM, Seeley, JR, Wagner, EF. Cigarette smoking, major depression, and other psychiatric disorders among adolescents. J Am Acad Child Adolesc Psychiatry. 1996; 35: 1602-1610.
  • Buchkremer, G, Bents, H, Horstmann, M et al. Combination of behavioral smoking cessation with transdermal nicotine substitution. Addict Behav. 1989; 14: 229-238.
  • Bundesärztekammer in Zusammenarbeit mit der Kassenärztlichen Bundesvereinigung. Frei von Tabak – Ein Stufenprogramm zur Raucherberatung und Rauchertherapie in der Arztpraxis, 3. überarbeitete Auflage. Köln. 2001.
  • Cook, DG, Strachan, DP. Summary of effects of parental smoking on the respiratory health of children and implications for research. Thorax. 1999; 54: 357-366.
  • Corty, E, Mc Fall, R. Response prevention in the treatment of cigarette smoking. Addict Behav. 1984; 9: 405-408.
  • Curry, SJ. Self-help interventions for smoking cessation. J Consult Clin Psychol. 1993; 61: 790-803.
  • David, S, Lancaster, T, Stead, LF. Narcotic antagonists for smoking cessation (Protocol for a Cochrane Review). In: The Cochrane Library,Issue 2, Update Software, Oxford. 2001.
  • Dempsey, DA, Benowitz, NL. Risks and benefits of nicotine to aid smoking cessation in pregnancy. Drug Saf. 2001; 24: 277-322.
  • Di Chiara, G, Imperato, A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci. 1988; 85: 5274-5278.
  • Di Franza, JR, Rigotti, NA, Mc Neill, AD et al. Initial symptoms of nicotine dependence in adolescents. Tobacco Control. 2000; 9: 313-319.
  • Dilling, H, Monbour, W, Schmidt, MH (Hrsg. ) Internationale Klassifikation psychischer Störungen: ICD-10, Kapitel V (F). Huber, Göttingen. 1991.
  • Diwan, A, Castine, M, Pomerleau, CS, Meador-Woodruff, JH, Dalack, GW. Differential prevalence of cigarette smoking in patients with schizophrenic vs mood disorders. Schizophr Res. 1998; 33: 113-118.
  • Edwards, NB, Murphy, JK, Downs, AD et al. Doxepin as an adjunct to smoking cessation: A double-blind pilot study. Am J Psychiatry. 1989; 146: 373-376.
  • Eichelberg, D, Stolze, P. Hautreaktionen bei transdermaler Nikotinsubstitution. In: Raucherentwöhnung – psychologische und
    pharmakologische Methoden. Buchkremer, G, Rath, N (Hrsg.). Thieme, Stuttgart, New York. 1989: S. 108-112.
  • Fagerström, KO, Heatherton, TF, Kozlowski, LT. Nicotine Addiction and Its Assessment. Ear, Nose Throat J. 1991, 69 (11): 763-768.
  • Fagerström, KO, Kunze, M, Schoberberger, R Nicotine dependence versus smoking prevalence: comparison among countries and categories of smokers. Tobacco Control. 1996; 5: 52-56.
  • Fagerstrom, KO, Schneider, NG. Measuring nicotine dependence: A review of the Fagerstrom Toleance Questionaire. J Behav Med. 1989; 12: 159 – 182.
  • Fagerström, KO, Tejding, R, Westin, Å et al. Aiding reduction of smoking with nicotine replacement medications: hope for the recalcitrant smoker? Tobacco Control. 1997; 6: 311-316.
  • Ferry, LH, Burchette, RJ. Evaluation of bupropion versus placebo for treatment of nicotine dependence. Oral presentation at the Annual Meeting of the American Psychiatric Association NR 554. 26. 5. 1994.
  • Ferry, LH, Robbins, AS, Scariati, PD. Enhancement of smoking cessation using the antidepressant bupropion hydrochloride. Circulation. 1992; 86: 167.
  • Fiore, MC, Bailey, WC, Cohen, SJ et al. Treating Tobacco Use and Dependence. Clinical Practice Guideline. Rockville, MD: US
    Department of Health and Human Services, Am J Public Health Service. 2000.
  • Fiore, MC, Smith, SS, Jorenby, DE et al. TB. The effectiveness of the nicotine patch for smoking cessation. JAMA. 1994; 271: 1940-1947.
  • Glasgow, RE, Lichtenstein, E. Long-term effects of behavioral smoking cessation interventions. Behav Ther. 1987; 18: 297-324.
  • Glassman, AH, Covey, LS, Dalack, GW et al. Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers. Clin Pharmacol Ther. 1993; 54: 670-679.
  • Glassman, AH, Stetner, F, Walsh, T et al. Heavy smokers, smoking cessation, and clonidine. Results of a double-blind, randomized trial. JAMA. 1988; 259: 2863-2866.
  • Glover, ED, Dachs, DPL, Stitzer, ML et al. J. Smoking cessation in highly dependent smokers with 4 mg nicotine polacrilex. Am J Health Behav. 1996; 20: 319-332.
  • Glynn, TJ, Manley, MW. How to help your patients to stop smoking. A National Cancer Institute Manual for Physicians. Washington: US Departement of Health and Human Services. 1989.
  • Goff, DC, Henderson, DC, Amico, D. Cigarette smoking in schizophrenia: Relationship to psychopathology and medication side effects. Am J Psychiatry. 1992; 149: 1189-1194.
  • Gould, RA, Clum, GA. A meta-analysis of self-help treatment approaches. Clin Psychol Rev. 1993; 13:169-186.
  • Gourlay, SG, Forbes, A, Marriner T et al. J. A placebo-controlled study of three clonidine doses for smoking cessation. Clin Pharmacol Ther. 1994a; 55: 64-69.
  • Gourlay, SG, Stead, LF, Benowitz, NL. Clonidine for smoking cessation (Cochrane Review). In: The Cochrane Library, Issue 2, Update Software, Oxford. 2001.
  • Green, JP, Lynn, SJ. Hypnosis and suggestion-based approaches to smoking cessation: an examination of the evidence. Int J Clin Exp Hyn. 2000; 48: 195-224.
  • Hajek, P, Belcher, M, Stapleton, J. Enhancing the impact of groups: an evaluation of two group formats for smokers. Br J Clin Psychol. 1985; 24: 289-294.
  • Hajek, P, Stead, LF. Aversive smoking for smoking cessation (Cochrane Review). In: The Cochrane Library, Issue 2, Update Software, Oxford. 2001.
  • Hajek, P. Treatment for smokers. Addiction. 1994; 89:1543-1549.
  • Hall, SM, Munoz, RF, Reus, VI, Sees, KL. Nicotine, negative affect, and depression. Special Section: Clinical research in smoking
    cessation. J Consult Clin Psychol. 1993; 61: 761-767.
  • Hall, SM, Tunstall, CD, Vila, KL et al. Weight gain prevention and smoking cessation: cautionary findings. Am J Am J Public Health. 1992; 82: 799-803.
  • Hao, W, Young, D, Wie, H. Effect of clonidine on cigarette cessation and in the alleviation of withdrawal symptoms. Br J Addict. 1988; 83:1221-1226.
  • Haustein, KO. Pharmacotherapy of nicotine dependence. Int J Clin Pharmacol Ther. 2000; 38, 273- 290.
  • Hays, JT, Hurt, RD, Wolter, TD et al. Bupropion-SR for relapse prevention [abstract]. Society for Research on Nicotine and Tobacco Annual Conference. 2000 Feb 18-20; Arlington VA, 2000.
  • Heatherton, TF, Kozlowski, LT, Frecker et al. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addiction. 1991; 86: 1119-1127.
  • Hilleman, DE, Mohiuddin, SM, Delcore, MG et al. Randomized, controlled trial of transdermal clonidine for smoking cessation. Ann Pharmacother. 1993; 27(9):1025-8.
  • Hjalmarson, A, Franzon, M, Weszin, A et al. Effect of nicotine nasal spray on smoking cessation. Arch Int Med. 1994; 154: 2567-2572.
  • Hjalmarson, A, Nilsson, F, Sjöström, L, Wiklund, O. The nicotine inhaler in smoking cessation. Arch Intern Med. 1997; 157:1721-1728.
  • Hughes, JR, Hatsukami, DK. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry. 1986; 43: 289-294.
  • Hughes, JR, Stead, LF, Lancaster, T. Antidepressants for smoking cessation (Cochrane Review). In: The Cochrane Library, Issue 2, Update Software, Oxford. 2001.
  • Hughes, JR, Stead, LF, Lancaster, T. Anxiolytics for smoking cessation (Cochrane Review). In: The Cochrane Library, Issue 2, Update Software, Oxford 2001.
  • Hughes, JR. Non-nicotine pharmacotherapies for smoking cessation. J Drug Dev. 1994; 6: 197-203.
  • Hughes, JR. Reduced smoking: an introduction and review of the evidence. Addiction. 2000; 95 (Suppl 1): 3-7.
  • Hurt, RD et al. Nicotine patch therapy in 101 adolescent smokers: efficacy, withdrawal symptom relief, and carbon monoxide and plasma cotinine levels. Arch Ped Adolescent Med. 2000; 154: 31-38.
  • Hurt, RD et al. Temporal effects of nicotine nasal spray and gum on nicotine withdrawal symptoms. Psychopharmacol. 1998; 140: 98-104.
  • Hurt, RD, Croghan, GA, Wolter, TD et al. Does smoking result in reduction of biomarkers associated with harm? A pilot study using a nicotine inhaler. Nicotine & Tobacco Research. 2000; 2: 327-336.
  • Hurt, RD, Dale, LC, Offord, KP, Croghan, IT, Hays, JT, Gomez-Dahl, L. Nicotine patch therapy for smoking cessation in recovering alcoholics. Addiction. 1995; 90: 1541-1546.
  • Hurt, RD, Offord, KP, Croghan, IT et al. Temporal effects of nicotine nasal spray and gum on nicotine withdrawal symptoms.
    Psychopharmacol. 1998; 140: 98-104.
  • Hurt, RD, Sachs, D, Glover, ED A comparison of sustained-release Bupropion and Placebo for smoking cessation. N Engl J Med. 1997; 337: 1195-202.
  • Hymowitz, N, Eckholdt, H. Effects of a 2. 5-mg silver acetate lozenge on initial and long-term smoking cessation. Prev Med. 1996; 25:537-546.
  • International Consultation on Environmental Tobacco Smoke (ETS) and Child Health. Consultation Report (http://tobacco. who.int/en/health/papers/ets-report. pdf). World Health Organization, Geneva. 1999.
  • Jensen, EJ, Schmidt, E, Pedersen, B et al. Effect on smoking cessation of silver acetate, nicotine and ordinary chewing gum. Influence of smoking history. Psychopharmacol Berl. 1991a;104: 470-474.
  • Jensen, EJ, Schmidt, E, Pedersen, B et al. The effect of nicotine, silver acetate, and placebo chewing gum on the cessation of smoking. The influence of smoking type and nicotine dependence. Int J Addict. 1991b; 26: 1223-1231.
  • John, U, Hanke, M. Tobacco smoking- and alcohol drinking-attributable cancer mortality in Germany. Eur J Cancer Prev. 2002; 11: 11-17.
  • Jorenby, DE, Leischow, SJ, Nides, MA et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999; 340: 685-689.
  • Joseph, AM et al. The safety of transdermal nicotine as an aid to smoking in patients with cardiac disease. N Engl J Med. 1996; 335: 1792-1798.
  • Joseph, AM, Nichol, KL, Anderson, H: Effect of treatment for nicotine dependence on alcohol and drug treatment outcomes. Addict Behav. 1993; 18: 635-644.
  • Junge, B, Nagel, M. Das Rauchverhalten in Deutschland. Das Gesundheitswesen. 1999. 61: 121-125.
  • Junge, B. Passivrauchen: Wie gefährlich ist es wirklich? Pharm Ztg. 1997; 142:1791-1800.
  • Kendler, KS, Neale, MC, MacLean, CJ, Heath, AC, Eaves, LJ, Kessler, RC. Smoking and major depression: A causal analysis. Arch Gen Psychiatry. 1993; 50: 36-43.
  • Klesges, LM, Johnson, KC, Ward, KD et al. Smoking cessation in pregnant women. Obstet Gynecol Clin North Am. 2001; 28: 269-282.
  • Kornitzer, M, Boutsen, M, Dramaix, M et al. G. Combined use of nicotine patch and gum in smoking cessation: A placebo-controlled clinical trial. Prev Med. 1995; 24: 41-47.
  • Kozlowski, LT, Wilkinson, A, Skinner, W et al. Comparing tobacco cigarette dependence with other drug dependencies. JAMA. 1989; 261: 898-901.
  • Kraus, L, Augustin, R. Repräsentativerhebung zum Gebrauch psychoaktiver Substanzen bei Erwachsenen in Deutschland 2000. Sucht. 2001; 47, Sonderheft 1.
  • Kröger, C. Raucherentwöhnung in Deutschland. Bundeszentrale für Gesundheitliche Aufklärung, Köln. 2000.
  • Kunze, M, Schoberberger, R. Nikotinabhängigkeit der Österreichischen Bevölkerung. Institut der Sozialmedizin, Universität Wien. 1994.
  • Lancaster, T, Stead, L, Silagy, C et al. A for the Cochrane Tobacco Review Group. Effectiveness of interventions to help people to stop smoking: findings from the Cochrane Library. Brit Med J. 2000; 321: 355-358.
  • Lancaster, T, Stead, LF. Individual behavioral counselling for smoking cessation. In: The Cochrane library, Issue 1, Upate Software, Oxford. 2001.
  • Lancaster, T, Stead, LF. Mecamylamine (a nicotine antagonist) for smoking cessation (Cochrane Review). In: The Cochrane Library, Issue 2, Update Software. 2001a.
  • Lancaster, T, Stead, LF. Self-help interventions for smoking cessation. (Cochrane Review). In: The Cochrane Library, Issue 3, Update Software, Oxford. 2001b.
  • Lancaster, T, Stead, LF. Silver acetate for smoking cessation (Cochrane Review). In: The Cochrane Library, Issue 2, Update Software, Oxford. 2001c.
  • Law, M, Hackshaw, AK. Environmental tobacco smoke. Br Med Bull. 1996; 52: 22-34.
  • Law, M, Tang, JL. An analysis of the effectiveness of interventions intended to help people stop smoking. Arch Int Med. 1995; 155: 1933-1941.
  • Leischow, SJ, Sachs, DPL, Bostrom, AG et al. Effects of differing nicotine-replacement doses on weight gain after smoking cessation. Arch Fam Med. 1992; 1: 233-237.
  • Lichtenstein, E, Glasgow, RE, Abrams, DB Social support in smoking cessation: In search of effective interventions. Behav Ther. 1986; 11, 439 – 442.
  • Lichtenstein, E, Glasgow, RE, Lando, HA et al. Telephone counselling for smoking cessation: rationale and review of evidence. Health Educ Res. 1996; 11: 243-257.
  • Lightwood, JM, Glantz, SA. Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke. Circulation. 1997; 96: 1089-1096.
  • Lindinger, P. Die Rauchersprechstunde – Beratungskonzepte für Gesundheitsberufe. Rote Reihe Tabakprävention und Tabakkontrolle. Deutsches Krebsforschungszentrum, Heidelberg, 2000.
  • Lowe, M, Green, L, Kurtz, S. et al. Self-initiated, cue extinction, and covert sensitization procedures in smoking cessation. J Behav Med. 1980; 3: 357-372.
  • Lumley, J, Oliver, S, Waters, E. Interventions for promoting smoking cessation during pregnancy (Cochrane Review). In: The Cochrane Library, Issue 3, Update Software, Oxford, 2001.
  • Mahmarian, JJ, Moye, LA, Nasser, GA et al. A strategy of smoking cessation combined with nicotine patch therapy reduces the extent of exercise-induced myocardical ischemia. J Am Coll Cardiol. 1998; 30: 125-130.
  • Malcolm, RE, Currey, HS, Mitchell, MA et al. Silver acetate gum as a deterrent to smoking. Chest. 1986; 90: 107-111.
  • Marcus, BH, Albrecht, AE, Niaura, RS et al. Exercise enhances the maintenance of smoking cessation in women. Addict Behav. 1995; 20: 87-92.
  • May, S, West, R. Do social support intervention (“buddy system”) aid smoking cessation? A review Tob Control. 2000; 9: 415-422.
  • Mc Robbie, H, Hajek, P. Nicotine replacement therapy in patients with cardiovascular disease: guidelines for health professionals. Addict. 2001; 96: 1547-1551.
  • Murphy, JK, Edwards, NB, Downs, AD et al. Effects of doxepin on withdrawal symptoms in smoking cessation. Am J Psychiatry. 1990; 147: 1353-1357.
  • Murray, RP et al. Safety of nicotine polacrilex gum used by 3, 094 participants in the Lung Health Study. Chest. 1996; 109: 438-445.
  • Niaura, R, Abraham, DB, Shadel, WG et al. Cue exposure treatment for smoking relapse prevention: a controlled clinical trial. Addict. 1999; 94: 685-695.
  • Niaura, R, Brown, RA, Goldstein, MG et al. Transdermal clonidine for smoking cessation – a double-blind randomised dose-response study. Exp Clin Psychopharmacol. 1996; 4:285-291.
  • Ockene, JK, Emmons, KM, Mermelstein, RJ et al. Relapse and Maintenance Issues for smoking cessation. Health Psychol. 2000; 19: 17-31.
  • Ogburn, PL et al. Nicotine patch use in pregnant smokers: nicotine and cotinine levels and fetal effects. Obstet Gynecol Clin North Am. 1999; 181: 736-743.
  • Oncken, CA et al. Effects of short-term use of nicotine gum in pregnant smokers. Clin Pharmacol Ther. 1996; 59: 654-661.
  • Oncken, CA et al. Effects of transdermal nicotine or smoking on nicotine concentrations and maternal-fetal hemodynamic effects. Obstet Gynecol Clin North Am. 1997; 90: 569-574.
  • Orleans, CT, Schoenbach, VJ, Wagner, EH et al. Self-help quit smoking interventions: effects of self-help materials, social support instructions and telephone counselling. J Consult Clin Psychol. 1991; 59: 439-448.
  • Park, E-W, Schultz, JK, Tudiver, F et al. Enhancing partner support to improve smoking cessation (Cochrane Review) The Cochrane Library, Issue 2, Update Software, Oxford, Ltd. All rights reserved. 2002.
  • Peto, R, Lopez, AD, Boreham, J et al. Mortality from smoking worldwide. Br Med Bull. 1996; 52:12-21.
  • Picardi, A et al. Association between the Engagement of Relatives in a Behavioural Group Intervention for Smoking Cessation and Higher Quit Rates at 6, – 12- and 24-Month Follow-Ups. Europ Addict Res. 2002; 8: 109-117.
  • Pieri, PL, Mc Bride, CM, Hellerstedt, W et al. Smoking cessation in women concerned about weight. Am J Am J Public Health. 1992; 82: 1238-1243.
  • Poehlke, T, Flenker, I, Reker, M, Reker, T, Kremer, G, Batra A (Hrsg.) Suchtmedizinische Versorgung 3: Alkohol – Tabak – Medikamente. Springer, Berlin Heidelberg New York 2000.
  • Prochaska, JO, Di Clemente, CC, Velicer, WF et al. Rossi JS: Standardized, individualized, interactive and personalized self-help programs for smoking cessation. Health Psychol. 1993; 12: 399-405.
  • Prochaska, JO, Di Clemente, CC. Stages and processes of self-change of smoking. Toward an integrative model of change. J Cons Clin Psychol. 1983; 51(3): 390 – 395.
  • Prochaska, JO, Velicer,WF. The transtheoretical model of health behavior change. Am J Health Promot. 1997 12: 38-48.
  • Puska, P et al. Combined use of nicotine patch and gum compared with gum alone in smoking cessation: a clinical trial in North Karelia. Tobacco Control. 1995; 4: 231-235.
  • Puska, PMJ, Brath, H, Astbury, C et al. Bupropion SR (Zyban®) is an effective and well-tolerated aid to smoking cessation in a population of healthcare professionals. 3rd European Meeting of the Society for Research on Nicotine and Tobacco – Europe, Paris, 19. – 22. 9. 2001.
  • Rausch, JL, Nichinson, B, Lamke, C, Matloff, J. Influence of negative affect on smoking cessation treatment outcome: A pilot study. Br J Addict. 1990; 85: 929-933.
  • Raw, M, Anderson, P, Batra, A et al. Recommendations panel. WHO Europe evidence based recommendations on the treatment of tobacco dependence. Tobacco Control. 2002; 11: 44-46.
  • Raw, M, Jarvis, M, Feyerabend, C et al. Comparison of nicotine chewing gum and psychological treatments for dependent smokers. Br Med J. 1980; 281: 481-482.
  • Raw, M, Mc Neill, A, West, R. Smoking Cessation Guidelines for Health Professionals. Thorax. 1998; 53:Suppl. 5: 1-18.
  • Raw, M, Russell, MAH. Rapid smoking, cue exposure and support in the modification of smoking. Behav Res Ther. 1980; 18: 363-372.
  • Rose, JE, Behm, FM, Westman, EC et al. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin Pharmacol Ther. 1994; 56: 86-99.
  • Rose, JE, Behm, FM, Westman, EC. Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy. Exp Clin Psychopharmacol. 1998; 6: 331-343.
  • Rose, JE, Westmann, EC, Behm, FM. Nicotine/Mecamylamine combination treatment for smoking cessation. Drug Dev Res. 1996; 38: 243-256.
  • Rosengren, A, Wilhelmsen, L, Wedel, H. Separate and combined effects of smoking and alcohol abuse in middle-aged men. Acta Med Scand. 1988; 223:111-118.
  • Russell, MA, Wilson, C, Taylor, C et al. Effect of general practitioners´ advice against smoking. BMJ. 1979; 2: 231 – 235.
  • Sachs, DPL. Advances in smoking cessation treatment. Curr Pulm. 1991; 12: 139-198.
  • Saß, H, Wittchen, HU, Zaudig, M. Diagnostisches und Statistisches Manual Psychischer Störungen DSM IV. Hogrefe, Göttingen, Bern, Toronto, Seattle. 1996.
  • Schmidt LG. Tabakabhängigkeit und ihre Behandlung. Dt Ärzteblatt. 2001;98: 1826-1833.
  • Schneider, NG, Olmstead, R, Mody, FV, Doan, K, Franon, M, Jarvik, ME, Steinberg, C. Efficacy of a nicotine nasal spray in smoking cessation: A placebo controlled, double blind trial. Addiction. 1995; 90:1671-1682.
  • Schneider, NG, Olmstead, R, Nilsson, F, Mody, FV, Franzon, M, Doan, K. Efficacy of a nicotine inhaler in smoking cessation: A double blind, placebo-controlled trial. Addiction. 1996; 91:1293-1306.
  • Schoberberger, R, Kunze, M. Nikotinabhängigkeit. Diagnostik und Therapie. Springer, Wien, New York. 1999.
  • Schumann, A, Hapke, U, John, U. Selbsthilfemanuale zur Raucherentwöhnung: Bewertung anhand inhaltlicher und formaler Kriterien. Sucht. 1999; 45: 250-262.
  • Schwartz, JL. Methods of smoking cessation. Med Clin North Am. 1992; 76: 451-476.
  • Sees, KL, Clark, HW: When to begin smoking cessation in substance abusers. J Subst Abuse Treat. 1993; 10: 189-195.
  • Silagy, C, Lancaster, T, Stead, L et al. Nicotine replacement therapy for smoking cessation (Cochrane Review) In: The Cochrane Library, Issue 3, Update Software, Oxford. 2001.
  • Silagy, C. Physician advice for smoking cessation (Cochrane Review). In: The Cochrane Library, Issue 4, Update Software, Oxford. 2000.
  • Silagy, CA, Mant, DC, Fowler, GH et al. Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet. 1994; 343: 139-142.
  • Smith, TA. et al. Nicotine patch therapy in adolescent smokers. Pediatrics. 1996; 98: 659-667.
  • Stage, KB, Glassman, AH, Covey, LS. Depression after smoking cessation: Case reports. J Clin Psychiatry. 1996; 57: 467-469.
  • Stahl, MMS, Wohlfahrt, B, Pahlm, O. Tolerability of concurrent use of nicotine gum and smoking in healthy volunteers. Nicotine & Tobacco Research. 2001; 3: 157-165.
  • Statistisches Bundesamt. Fragen zur Gesundheit 1999: Metzler-Pöschel, Stuttgart. 2000.
  • Stead, LF, Hughes, JR. Lobeline for smoking cessation (Cochrane Review). In: The Cochrane Library, Issue 2, Update Software, Oxford. 2001.
  • Stead, LF, Lancaster, T. Group behaviour therapy programmes for smoking cessation (Cochrane Review) In: The Cochrane Library, Issue 3, Update Software, Oxford, 2001b.
  • Stead, LF, Lancaster, T. Individual behavioral counselling for smoking cessation (Cochrane Review). In: The Cochrane Library, Issue 1, Update Software, Oxford, 2001a.
  • Strecher, VJ, Kreuter, M, Den Boer, DJ et al. The effects of computer-tailored smoking cessation messages in family practice settings. J Fam Pract. 1994; 39: 262-270.
  • Sutherland, G, Stapleton, JA, Russell, MAH et al. Randomised controlled trial of nasal nicotine spray in smoking cessation. Lancet. 1992; 340: 324-329.
  • Sutherland, G, Stapleton, JA. Nasal nicotine spray for dependent smokers. J Smoking-Related Dis. 1994; 5: 195-201.
  • Swan, GE, Parker, SD, Chesney, MA et al. Reducing the confounding effect of environment and diet on salvia thiocyanate values in ex-smokers. Add Behav. 1985; 10: 187 -190.
  • Swartz, H, Cohen, A. Clinical evaluation of SmoKurb as a smoking deterrent. Curr Ther Res. 1964; 6(4): 290-296.
  • Ter Riet, G, Kleijnen, J, Knipschild, P. A meta-analysis of studies into the effect of acupuncture on addiction. Br J Gen Pract. 1990; 40:379-382.
  • Tønnesen, P, Fryd, V, Hansen, M, Helsted, J. Two and four mg nicotine chewing gum and group counselling in smoking cessation: An open, randomized, controlled trial with a 22 month follow-up. Addict Behav. 1988; 13:17-27.
  • Tzivoni, D et al. Cardiovascular safety of transdermal nicotine patches in patients with coronary artery disease who try to quit smoking. Cardiovascular Drug Ther. 1998; 12: 239-244.
  • US Department of Health an Human Services. Drug Abuse and Drug Abuse Research. The Second Triennial Report to Congress from the Secretary. US Department of Health and Human Services, Am J Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute on Drug Abuse. DHHS Publication No. (ADM). 1987.
  • US Department of Health and Human Services. Reducing the health consequences of smoking: 25 years of progress. A report of the Surgeon General. Rockville, MD: US Department of Health and Human Services. 1989.
  • US Department of Health and Human Services. Treating Tobacco Use and Dependence – a Clinical Practice Guideline. US Government Printing Office, Washington, DC. 2000.
  • Ussher, MH, West, R, Taylor, AH et al. Excercise intervention for smoking cessation. In: The Cochrane Library, Issue 1, Upate Software, Oxford. 2001.
  • Villagra, VG, Rosenberger, JL, Girolami, S. Transdermal clonidine for smoking cessation: A randomised, double blind, placebo controlled trial. Circulation. 1989; 80 (Suppl II): 4-58.
  • Viswesvaran, C, Schmidt, FL. A meta-analytic comparison of the effectiveness of smoking cessation methods. J Appl Psychol. 1992; 77: 554-561.
  • Viswesvaran, C, Schmidt, FL. A meta-analytic comparison of the effectiveness of smoking cessation methods. J Appl Psychol. 1992; 77: 554-561.
  • Wallström, M, Nilsson, F, Hirsch, JM. A double-blind placebo controlled clinical evaluation of a nicotine sublingual tablet in smoking cessation [abstract 2822]. European Respiratory Society Meeting: Berlin 1997 Sept 20-24.
  • Wallström, M, Sand, L, Nilsson, F. The long-term effect of nicotine on the oral mucosa. Addict. 1999; 94: 417-423.
  • Watkins, SS, Koob, GF, Markou, A. Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine & Tobacco Research. 2000; 2:19-38.
  • Welte, R, König, HH, Leidl, R. The costs of health damage and productivity losses attributable to cigarette smoking in Germany. Eur J Public Health. 2000; 10: 31-38.
  • Weltgesundheitsorganisation: Internationale Klassifikation psychischer Störungen. ICD-10 Kapitel V (F). Übersetzt und herausgegeben von H. Dilling, W. Mombour, MH. Schmidt. 1993, Huber, Bern (2. Auflage).
  • West, R, Mc Neill, A, Raw, M. Smoking cessation guidelines for health professionals: an update. Thorax. 2000; 55: 987-999.
  • White, AR, Rampes, H, Ernst, E. Acupuncture for smoking cessation (Cochrane Review). In: The Cochrane Library, Issue 2, Update Software, Oxford, 2001.
  • Wisborg, K, Henriksen, TB, Jespersen, LB. Nicotine patches for pregnant smokers: a randomised controlled study. Obstet Gynecol Clin North Am. 2000; 96: 967-971.
  • Working Group for the Study of Transdermal Nicotine in Patients with Coronary Artery Disease. Nicotine replacement therapy for patients with coronary artery disease. Arch Int Med. 1994; 154: 989-995.
  • World Health Organization. First WHO Recommendations on the Treatment of Tobacco Dependence. WHO Regional Office. Copenhagen. 2001.
  • World Health Organization. Regulation of Nicotine Replacement Therapies: An Expert Consensus. Copenhagen. 2001.
    196. World Health Organization. Tobacco or Health: A global status report. WHO, Genf. 1997.
  • Wright, LN et al. Transdermal nicotine replacement in pregnancy: Maternal pharmacokinetics and fetal effects Obstet Gynecol Clin North Am. 1997; 176: 1090-1094.
  • Zarin, DA, Pincus, HA, Mc Intyre JS. Practice Guideline for the Treatment of Patients with Nicotine Dependence. Am Psychiatry Ass. 2000.